__timestamp | Amneal Pharmaceuticals, Inc. | Halozyme Therapeutics, Inc. |
---|---|---|
Wednesday, January 1, 2014 | 335989000 | 22732000 |
Thursday, January 1, 2015 | 367054000 | 29245000 |
Friday, January 1, 2016 | 420770000 | 33206000 |
Sunday, January 1, 2017 | 507476000 | 31152000 |
Monday, January 1, 2018 | 946588000 | 10136000 |
Tuesday, January 1, 2019 | 1273376000 | 45546000 |
Wednesday, January 1, 2020 | 1364130000 | 43367000 |
Friday, January 1, 2021 | 1324696000 | 81413000 |
Saturday, January 1, 2022 | 1427596000 | 139304000 |
Sunday, January 1, 2023 | 1573042000 | 192361000 |
Monday, January 1, 2024 | 159417000 |
Cracking the code
In the ever-evolving pharmaceutical landscape, understanding cost structures is pivotal. Over the past decade, Amneal Pharmaceuticals, Inc. and Halozyme Therapeutics, Inc. have showcased contrasting expense trajectories. Amneal's cost of revenue surged by approximately 368% from 2014 to 2023, reflecting its aggressive market expansion and production scaling. In contrast, Halozyme's expenses grew by nearly 747% during the same period, indicating strategic investments in innovation and development.
Amneal's cost of revenue consistently climbed, peaking in 2023, underscoring its commitment to broadening its product portfolio. Meanwhile, Halozyme's expenditure spike in recent years highlights its focus on pioneering therapeutic solutions. This financial narrative not only reveals the companies' strategic priorities but also offers investors a lens into their operational efficiencies and market positioning.
As the pharmaceutical industry continues to innovate, these insights provide a window into the fiscal strategies driving two of its key players.
Novo Nordisk A/S vs Halozyme Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Gilead Sciences, Inc. vs Amneal Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Bio-Techne Corporation vs Halozyme Therapeutics, Inc.
Cost Insights: Breaking Down Sarepta Therapeutics, Inc. and Halozyme Therapeutics, Inc.'s Expenses
Cost of Revenue Trends: Walgreens Boots Alliance, Inc. vs Amneal Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Halozyme Therapeutics, Inc. and Pharming Group N.V.
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs ACADIA Pharmaceuticals Inc.
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Mesoblast Limited's Expenses
Halozyme Therapeutics, Inc. vs Galapagos NV: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Halozyme Therapeutics, Inc. vs MiMedx Group, Inc.
Cost of Revenue Trends: Amneal Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.
Cost of Revenue Comparison: Amneal Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.